[Effect of the raloxifene versus combined hormonal therapy on the mammary density]

Author(s): Linares-Segovia B, Rodriguez-Osorio JA, Storms-Salas G, Cervantes-Villarreal E

Affiliation(s): Facultad de Medicina de Leon, Universidad de Guanajuato, Unidad de Investigacion en Epidemiologia Clinica, IMSS, Guanajuato. blinares@salud.gob.mx

Publication date & source: 2008-01, Rev Med Inst Mex Seguro Soc., 46(1):51-4.

Publication type: Comparative Study; English Abstract; Randomized Controlled Trial

OBJECTIVE: to compare in postmenopausal women with osteoporosis or osteopenia the effect of hydrochlorate of raloxifene versus hormone replacement therapy on the mammary density. METHOD: a double blind, randomized clinical trial was conducted in 57 postmenopausal women older than 55 years with osteoporosis or osteopenia. Participants were randomly allocated in two groups: the intervention group (IG) received hydrochlorate of raloxifene and the control group (CG) received hormone replacement therapy during 6 months. A mammography to evaluate the change of the mammary density, according to the BIRADS criteria, was made before and after the treatment. RESULTS: twenty-eight patients received hormone replacement therapy and 29 hydrochlorate of raloxifene. Eight (28.5 %) patients of the IG and one (3.0 %) of the CG showed an increased mammary density; whereas in none of IG patients and in four (13.7%) of the CG, the mammary density decreased (p = 0.01). CONCLUSIONS: the hydrochlorate of raloxifene in postmenopausal women with osteoporosis or osteopenia does not increase the mammary density.